Exome sequencing revealed that 79% of lesions (EC and/or DIE) carried mutations, with 26% involving ARID1A, PIK3CA, KRAS, or PPP2R1A, among which PIK3CA and KRAS are frequently altered in ovarian cancer [100]. This evidence concerns the gene KRAS and ovarian cancer.